A5041400856- Vaccine Coverage and Hesitancy
- Research on Leishmaniasis Studies
- Virology and Viral Diseases
- SARS-CoV-2 and COVID-19 Research
- Cervical Cancer and HPV Research
- Parasites and Host Interactions
- COVID-19 epidemiological studies
- Hepatitis B Virus Studies
- Global Maternal and Child Health
- Neonatal and Maternal Infections
- Viral Infections and Outbreaks Research
- Salmonella and Campylobacter epidemiology
- Pneumonia and Respiratory Infections
- Vibrio bacteria research studies
- Viral gastroenteritis research and epidemiology
- Immunodeficiency and Autoimmune Disorders
- Gene expression and cancer classification
- Trypanosoma species research and implications
- Virus-based gene therapy research
- COVID-19 Digital Contact Tracing
- Prion Diseases and Protein Misfolding
- Mobile Health and mHealth Applications
- Immune responses and vaccinations
- Data-Driven Disease Surveillance
- Fecal contamination and water quality
BH Consulting (Ireland)
2024
Over the past decade, several countries across all regions, income groups and procurement methods have been unable to secure sufficient BCG vaccine supply. While frequency of stock-outs has remained rather stable, duration increased in 2014-2015 due manufacturing issues attracted attention national, regional global immunization stakeholders. This prompted an in-depth analysis supply demand dynamics aiming characterize risks. is unique as it provides a picture, where previous analyses focused...
Leishmania infections are global, occurring in 98 countries and all World Health Organization (WHO) regions with 600 million to 1 billion people at risk of infection. Visceral leishmaniasis is associated almost 20,000 reported deaths annually, children under 5 years age being the greatest mortality. Amongst WHO-recognised Neglected Tropical Diseases (NTDs), one most important terms mortality morbidity. With an increasing global burden disease a growing threat from climate change,...
The development of vaccines against one or all forms human leishmaniasis remains hampered by a paucity investment, at least in part resulting from the lack well-evidenced and agreed estimates vaccine demand. Starting definition 4 main use cases (prevention visceral leishmaniasis, prevention cutaneous post-kala-azar dermal treatment leishmaniasis), we have estimated size each target population, focusing on those endemic countries where incidence levels are sufficiently high to justify...
Background A pressing need exists to develop vaccines for neglected diseases, including leishmaniasis. However, the development of new is dependent on their value two key players–vaccine developers and manufacturers who have confidence in global demand order commit research production; governments (or other international funders) signal based potential public health benefits vaccine local context, as well its affordability. detailed epidemiological analysis rarely available before a enters...
Background: There is increasing interest in low-and middle-income countries (LMICs) to introduce and scale-up digital health tools like electronic immunization registries (eIR), logistics management information systems (eLMIS) support services. An evaluation of the use these was conducted four inform decisions about their further expansion investments. Methods: Purposive sampling regions, districts, facilities done each country based on predefined criteria. Primary data were collected...
Microarray patches (MAPs) are a promising technology being developed to reduce barriers vaccine delivery based on needles and syringes (N&S). To address the evidence gap public health value of applying this potential immunisation programmes, we evaluated impact measles burden cost-effectiveness introducing measles-rubella MAPs (MR-MAPs) in 70 low-income middle-income countries (LMICs).
Human visceral leishmaniasis (VL) vaccines are currently under development and there is a need to understand their potential impact on population wide VL incidence. We implement four characteristics from different human vaccine candidates into two published transmission model variants estimate the of these population-wide anthroponotic incidence Indian subcontinent (ISC). The that simulated in this study 1) reduce infectiousness infected individuals towards sand flies, 2) risk developing...
As of November 2023, 140 World Health Organization (WHO) member states had introduced human papillomavirus (HPV) vaccination in their routine immunization schedules. Despite a continuously increasing demand from countries across all income groups, supply constraints, COVID-19 pandemic disruptions, and other factors have slowed the pace introduction, particularly low-resource settings. Using population-based forecasting methodology leveraging WHO’s yearly vaccine data collection, we updated...
Progress toward measles and rubella (MR) elimination has stagnated as countries are unable to reach the required 95% vaccine coverage. Microarray patches (MAPs) anticipated offer significant programmatic advantages needle syringe (N/S) presentation increase MR vaccination A demand forecast analysis of doses (PDR) could accelerate MR-MAP development by informing size return investment manufacture MAPs.
Measles and rubella micro-array patches (MR-MAPs) are a promising innovation to address limitations of the current needle syringe (N&S) presentation due their single-dose presentation, ease use, improved thermostability. To direct accelerate further research interventions, an initial full value vaccine assessment (iFVVA) was initiated prior MR-MAPs entering phase I trials quantify identify key data gaps challenges. The iFVVA utilized mixed-methods approach with rapid literature,...
The Monitoring & Evaluation/Accountability (M&E/A) framework of the Global Vaccine Action Plan (GVAP) was used to report progress annually World Health Assembly (WHA). Stakeholder feedback obtained through five reviews consisting surveys and semi-structured interviews conducted from 2017 2019. Participants consisted individuals involved in development implementation GVAP or its M&E/A process, national immunization managers, academics, representatives non-governmental organizations, civil...
The Global Vaccine Action Plan (GVAP), unanimously endorsed by the World Health Assembly in 2012, defined an ambitious strategy to improve immunization. At end of decade, significant progress has been made but four five GVAP goals are likely be missed. This report describes a set surveys and interviews relating GVAP, conducted inform immunization for next decade. Three two sets semi-structured were from 2017 2019. Respondents consisted stakeholders at global, regional, country levels,...
Innovative vaccine products will be critical in helping to address the existing implementation barriers that have prevented achievement of measles and rubella (MR) coverage targets. Overcoming those necessary achieve "Immunization Agenda 2030" goals. Microarray patches (MAPs), an innovative needle-free delivery device currently clinical development, can a potential game changer this respect contribute equitable vaccines low- middle-income countries pandemic preparedness response. Developing...
Countries are recommended to immunise adolescent girls routinely with one or two doses of human papillomavirus (HPV) vaccines eliminate cervical cancer as a public health problem. With most existing vaccine absorbed by countries (mostly high-income) HPV vaccination programmes, limited supply has been left for new country introductions until 2022; many those, low- and middle-income higher mortality. Several strategies were considered the Strategic Advisory Group Experts on Immunization allow...
Abstract The development of vaccines against one or all forms human leishmaniasis remains hampered by a paucity investment, at least in part resulting from the lack well-evidenced and agreed estimates vaccine demand. Starting definition 4 main use cases (prevention visceral leishmaniasis, prevention cutaneous post-kala-azar dermal treatment leishmaniasis), we have estimated size each target population, focusing on those endemic countries where incidence levels are sufficiently high to...
Abstract Background Despite group B Streptococcus (GBS) being a leading cause of maternal and infant morbidity mortality, no vaccine is currently available. To inform developers, countries, funders, we analyzed the key factors likely to influence demand for GBS long-term financial sustainability developer. Methods Using population-based forecasting, estimated vaccine; using discounted cash flow model viability Results Demand this can be significant if countries adopt policy recommendations...
Abstract Background Human visceral leishmaniasis (VL) vaccines are currently under development and there is a need to understand their potential impact on population wide VL incidence. Methodology / Principal Findings We implement four characteristics from different human vaccine candidates into two published transmission model variants estimate the of these population-wide anthroponotic incidence Indian subcontinent (ISC). The that simulated in this study 1) reduce infectiousness infected...
To inform the World Health Organization's full value of vaccine assessment for group B Streptococcus (GBS) vaccines, a rapid literature appraisal was conducted to operationalization maternal GBS vaccination. We found limited published information on stakeholder perceptions public health importance disease and vaccination, we therefore undertook multicountry survey.An online survey in late 2019 collect stakeholders' awareness priority accorded The distributed by email 395 representatives...
Download This Paper Open PDF in Browser Add to My Library Share: Permalink Using these links will ensure access this page indefinitely Copy URL DOI